Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.37B 10.84B 10B 9.24B 17.51B 1,180B 17.8B 119B 46.84B 581B 46.46B 45.45B 2,001B P/E 2026 *
-75.9x
P/E 2027 * 54.2x
Enterprise Value 11.84B 10.38B 9.57B 8.84B 16.76B 1,130B 17.04B 114B 44.83B 556B 44.47B 43.5B 1,915B EV / Sales 2026 *
7.92x
EV / Sales 2027 * 5.11x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day-4.16%
1 week+1.63%
Current month-0.05%
1 month+13.87%
3 months+3.29%
6 months+4.40%
Current year-7.84%
1 week 522.06
Extreme 522.06
569.44
1 month 469.08
Extreme 469.075
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 07/09/2023
Director of Finance/CFO 62 10/03/2024
Chief Tech/Sci/R&D Officer 58 20/04/2025
Director TitleAgeSince
Director/Board Member 74 30/06/2016
Director/Board Member 68 10/08/2016
Director/Board Member 64 26/06/2019
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Founder

1,220 0.0053%
06-16
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
06-16Free

Director

1,220 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
-4.16%+1.63%+70.58%+143.85% 12.37B
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -1.02%-0.09%+55.93%+148.15% 25.36B
Weighted average by Cap. -1.07%-1.31%+55.80%+138.10%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.21B 1.12B 2.12B 143B 2.15B 14.43B 5.66B 70.25B 5.61B 5.49B 242B 2.21B 1.93B 1.78B 1.65B 3.12B 210B 3.17B 21.29B 8.35B 104B 8.28B 8.1B 357B
Net income -201M -176M -162M -150M -284M -19.17B -289M -1.94B -761M -9.44B -755M -738M -32.5B 308M 270M 249M 230M 435M 29.34B 443M 2.97B 1.16B 14.45B 1.16B 1.13B 49.74B
Net Debt -529M -464M -427M -395M -749M -50.47B -761M -5.11B -2B -24.86B -1.99B -1.94B -85.56B -1.09B -959M -884M -817M -1.55B -104B -1.58B -10.56B -4.14B -51.43B -4.11B -4.02B -177B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
10/07/26 US$536.70 -4.16% 294,015
09/07/26 US$560.01 -0.95% 379,035
08/07/26 US$565.40 +3.67% 468,252
07/07/26 US$545.36 +3.00% 318,420
06/07/26 US$529.48 +0.26% 230,982
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
536.70USD
Average target price
678.71USD
Spread / Average Target
+26.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock